Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVRNA021 Booster in Adults
NCT05939648Phase 2Active, not recruiting
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LVRNA021 in coronavirus disease 2019 (COVID-19), sponsored by AIM Vaccine Co., Ltd.. Started Oct 2023; status: active, not recruiting.
02
Drugs
LVRNA021
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05939648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05939648.